突变状态对乳腺癌治疗中抑制剂的预测作用：系统评价和荟萃分析。

The Predictive Role of Mutation Status on Inhibitors in Breast Cancer Therapy: A Systematic Review and Meta-Analysis.

机构信息

Department of Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

出版信息

Biomed Res Int. 2020 May 10;2020:1598037. doi: 10.1155/2020/1598037. eCollection 2020.

AIM

To evaluate the impact of mutation status on clinical outcomes of breast cancer treated with inhibitors.

METHODS

A comprehensive literature search was conducted in online databases from inception to December 31, 2019. The main characteristics and prognostic data of each eligible study were extracted. The odds ratio (OR) for the overall response rate (ORR) and hazard ratio (HR) for progression-free survival (PFS) were estimated using the fixed-effects Mantel-Haenszel model.

RESULTS

A total of 8 studies involving 2670 patients were included for analysis. Overall, the clinical outcomes of inhibitors were significantly influenced by mutation status in breast cancer. After the treatment of inhibitors, breast cancer patients with mutations presented better ORR (mutated group: OR = 1.98 [95% CI, 1.46 to 2.70]; wild-type group: OR = 1.09 [95% CI, 0.78 to 1.53]) and better PFS (-mutated group: HR = 0.65 [95% CI, 0.55 to 0.76]; wild-type group: HR = 0.87 [95% CI, 0.70 to 1.09]). No publication bias was detected for ORR and PFS in our analysis.

CONCLUSION

In this meta-analysis, it suggests that the association between clinical outcomes of inhibitors and mutation status is dramatic. mutations were a favorable factor in the clinical outcomes of breast cancer treated with inhibitors.

目的

评估突变状态对接受抑制剂治疗的乳腺癌患者临床结局的影响。

方法

系统检索在线数据库，时间从建库至 2019 年 12 月 31 日。提取每项合格研究的主要特征和预后数据。采用固定效应 Mantel-Haenszel 模型估计总缓解率（ORR）和无进展生存期（PFS）的风险比（HR）。

结果

共纳入 8 项研究，总计 2670 例患者。总体而言，抑制剂的临床结局受乳腺癌突变状态显著影响。接受抑制剂治疗后，突变型乳腺癌患者的 ORR 更好（突变组：OR=1.98[95%CI，1.46 至 2.70]；野生型组：OR=1.09[95%CI，0.78 至 1.53]），PFS 更好（-突变组：HR=0.65[95%CI，0.55 至 0.76]；野生型组：HR=0.87[95%CI，0.70 至 1.09]）。本分析中，ORR 和 PFS 均未检测到发表偏倚。